Poop transplant plus drug shows promise against recurrent c. diff in IBD patients
NCT ID NCT03829475
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested whether adding a drug called bezlotoxumab to a fecal microbiota transplant (FMT) could better prevent repeat Clostridium difficile infections in people with inflammatory bowel disease (IBD). About 61 adults with at least two past C. diff infections took part. They received either FMT plus bezlotoxumab or FMT plus a placebo, and were followed for 3 months to see if the infection came back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.